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ABSTRACT
High-Risk Human Papillomavirus (HPV): An Emerging Health Issue for Women
and Minorities
by
Deidre O. Turner
Dr. Shawn Gerstenberger, Examination Committee Chair
Professor of Public Health
University of Nevada, Las Vegas - School of Community Health Sciences
Dr. Karl Kingsley, Examination Committee Co-Chair
Associate Professor of Biomedical Sciences
University of Nevada, Las Vegas - School of Dental Medicine
The human papillomavirus (HPV) is the cause of nearly all cases of cervical
cancers worldwide. HPV viral DNA is found in more than 99% of cervical cancers. In
addition to cervical cancer, HPV is also associated with some breast and oral cancers.
White women have been showing a decline in breast cancer rates while black women are
continuously showing higher rates of mortality from both breast and cervical cancer.
Minority women are also more likely to receive a late diagnosis and are showing
increased incidence of oral cancer, which makes study of HPV in women and minorities
significant.
To date, little evidence has been provided to estimate oral HPV prevalence among
healthy adults in the US. A few select international studies have evaluated HPV
prevalence in healthy adults using biopsy samples and these results show HPV
prevalence ranging from 0 – 15%. More recently, new international studies have begun
to report less invasive saliva-based testing methods to successfully screen for oral HPV
infection among healthy adults, revealing prevalence rates of approximately 20%. To
iii

date, there are no reports of saliva-based HPV screening studies of normal, healthy
adults, rather than oral cancer patients, to screen for oral prevalence in the U.S.
The goal of this study was to collect saliva from the University of Nevada Las
Vegas – School of Dental Medicine (UNLV-SDM) patient clinic and screen for the
presence of the high risk strain, HPV 16, found in the majority of HPV-associated
cervical, breast, and oral cancers. Two hundred participants were asked to provide a
saliva sample for HPV screening. Demographic information such as age, gender, and race
were also obtained for statistical analysis. DNA was isolated from the saliva sample in
order to perform PCR to screen for HPV 16.
Analysis of the UNLV-SDM patient population revealed a higher percentage of
females and minorities than in the local community, Clark County. Analysis of the
demographic information from the saliva samples revealed that these samples were
representative of the UNLV-SDM patient pool. Four (4) samples tested positive for
HPV16 (all from women and minority participants) from more than one hundred samples
screened (n=102). Although the prevalence of HPV16 in this study was relatively low
(3.9%), it is comparable to other studies of oral HPV (range 0 -21%).This study is
significant because it is the first saliva-based oral HPV screening on healthy adults to be
completed in the U.S. and only the third study of its kind overall.
Future studies might incorporate larger sample sizes and provide alternative sites
for screening other at-risk populations.
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CHAPTER 1
INTRODUCTION
Purpose of the Study & Specific Aim
The overall purpose of this research project was to screen University of Nevada
Las Vegas-School of Dental Medicine (UNLV-SDM) patients for oral HPV. UNLVSDM, with more than 90,000 active patients, is uniquely positioned to perform oral
screening and oral HPV testing among this patient population. A UNLV Office of
Research Integrity – Human Subjects protocol (#1002-3361- The Prevalence of Oral
Human Papilloma Virus in the UNLV School of Dental Medicine Clinic Population) has
been approved to sample and study HPV infection among these patients.
Background & Significance
HPV Background
HPV is a non-enveloped DNA virus. There are greater than 100 types of HPV
which are classified into low and high risk types. Low risk types of HPV are more
commonly associated with warts while high risk types of HPV are associated with
cancers. HPV is associated with many cancers, but for the purpose of this study, cervical,
breast, and oral cancers will be discussed. This study specifically focuses on HPV 16, a
high-risk strain, due to its presence in cervical, breast, and oral cancers. Even though
almost everyone gets infected with HPV, the immune system can rid itself of
papillomaviruses, but persistent viruses can develop into warts and even lead to cancer
(Kersiek , 2008). HPV 16 is the most prevalent strain in oral and breast cancers (Kingsley
et al., 2009).
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Cervical Cancer
Cervical cancer is a disease that is both preventable and curable. The
papanicolaou cytological test (Pap smear) is a screening tool used to detect abnormalities
in the cervix of women. If cervical cancer is detected early it can be cured. Screening is
imperative for all women, despite socioeconomic status. “Cervical cancer is a disease
most frequently found in poverty-stricken communities and reflecting a problem of
equity at both levels: gender and regional, and this is not only due to social and economic
development inequalities, but also due to the infrastructure and human resources
necessary for primary care” (Chankapa et al., 2011).
HPV is the cause for cervical cancer and has been linked to more than 99% of
cervical cancers (Andrews et al., 2008). According to the Centers for Disease Control and
Prevention (CDC), cervical cancer is the most common cancer associated with HPV
(CDC, 2009). Cervical cancer is the second most common cancer in women worldwide
(Verhoeven et al, 2009; Confertini et al., 2010). In the U.S., Black and Hispanic women
are at a higher risk for cervical cancer (Downs, 2010). Moreover, Black women may not
receive the best care available and therefore are more likely to die from cervical cancer
(Coker et al., 2009). According to a meta-analysis based on over fifty studies, individuals
with low socioeconomic status (SES) compared to individuals with a high SES had a
two-fold increased risk for cervical cancer (Benard et al., 2008). Risk factors for cervical
cancer include: age of first sexual contact, number of sexual partners, history of sexually
transmitted disease, diet, and environment. Gillison and Shah (2003) suggested that the
sexual practices of women, sexual practices of their male partners, and the standard of
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health care, in regards to an effective screening program, are the major factors related to
cervical cancer.
Breast Cancer
While breast cancer is the second most common cancer in the world, affecting one
in eight women, it is the leading type of cancer affecting women worldwide (Shukla,
2009). HPV is relevant in breast cancer since high risk types of HPV have been seen in
approximately 50% of breast cancer biopsies (Kingsley et al., 2009). Mammography is
the most effective method for detecting cancer of the breast(s). Often times minority
women do not get screened or are infrequently screened which can lead to a late
diagnosis and mortality risk. Even though mortality rates for breast cancer have been
steadily declining, rates for American Indian and Alaska Natives have been increasing
(Engelman et al., 2011). Possible barriers that may prevent screening are fear of pain,
beliefs, embarrassment, lack of insurance, and the ability to pay.
Oral HPV
Twenty five percent of oral cancers may be linked to HPV (CDC, 2009) with
HPV 16 being the most predominant type detected in oral cancers. Risk factors for oral
cancer may include: alcohol consumption, tobacco use, HPV, oral hygiene, diet, family
history, age, gender, and race. The main risk factors are alcohol and tobacco use, which is
a concern for minorities since minorities are more likely to use alcohol and tobacco
products. Cigarette smoking was first identified in 1957 as an independent risk factor for
oral and oropharyngeal cancer (Ragin et al., 2007). In essence, tobacco products were
confirmed, along with alcohol, as the two major risk factors for developing oral and
oropharyngeal cancers (Ragin et al., 2007). Furthermore, diets that do not meet the
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appropriate levels for fruit and vegetable consumption are also related to the risk of
developing oral cancer. Oral cancer is a major concern because the number of women
with oral and pharyngeal cancers is expected to increase well beyond cervical cancer
(Lyda, 2010).
Experimental Design
This study involves a prospective, cluster study design. This proposal involves
using a cluster sample, located at the UNLV School of Dental Medicine.

The

investigators selected patients for participation based upon the following criteria. The
inclusion criteria required participants to: be a current patient at UNLV-SDM; be over
eighteen years of age; agree to participate; and provide Informed Consent. The exclusion
criteria excluded participants under the age of 18 and those who did not wish to
participate.
Research Questions and Hypotheses
1. How does the UNLV-SDM patient population demographics (gender, race, age)
compare to the population of Southern Nevada (Clark County)?
Null hypothesis: There is no difference between UNLV-SDM and Clark County
population demographics
Alternative hypothesis: There is a difference between UNLV-SDM and Clark
County
2. How does the HPV screening sample demographics (gender, race, age) compare with
the UNLV-SDM patient population?
Null hypothesis: There is no difference between HPV sample and UNLV-SDM
population
Alternative hypothesis: There is a difference between HPV sample and UNLVSDM
3. What is the prevalence of high-risk HPV in the sample population?
No hypothesis: There is no current information for comparison
4. How does this study compare with published oral HPV prevalence?
4

Null hypothesis: There is no difference between UNLV sample and other oral
HPV studies
Alternative hypothesis: There may be a difference between UNLV sample and
other oral HPV studies; although it is not known whether this will be higher or
lower.
Predictions
It is predicted that there is a difference between UNLV-SDM demographics and
Clark County; There is no difference between HPV sample and UNLV-SDM population;
Since no current information is available, no comparison can be made on the prevalence
of high risk HPV in the sample population; and there is a difference between UNLV
sample prevalence and other oral HPV publications.
Preliminary Results
To answer the first research question, comparing the UNLV-SDM patient
population demographics (gender, race, age) to the population of Southern Nevada (Clark
County), US Census data were analyzed to determine the percentage of females,
minorities and those within specific age ranges. These results demonstrate that the
UNLV-SDM population was similar to Clark County with respect to gender, with
approximately equal percentages of females and males (Table 1.1). More specifically,
the percentage of females at UNLV-SDM was 50.6%, which is statistically higher than
the percentage in Clark County 49.1%, although this makes little practical significance.
The percentage of minorities, Blacks and Hispanics, were greater at UNLV-SDM (15.3%
and 41.4%) than in Clark County (10.6% and 29.3%). UNLV-SDM also had higher
percentages of patients 18-64 and 65+ (70.5% and 12.2%) compared with Clark County
(63% and 10.7%). These data demonstrate that UNLV-SDM has a significantly different
5

composition of patients than the surrounding community, therefore the alternative
hypothesis can be accepted.
Table 1.1 Demographic analysis of Clark County and UNLV-SDM
________________________________________________________________________
Variables

Clark County

Expected

Observed
UNLV-SDM

p-value

________________________________________________________________________
Gender
Female

N = 934,291 (49.1%)

(.491) 71,051
n = 34,886

50.6%
n = 35,952
X2 = 61.3
df = 1
p < 0.001

Male

N = 966,640 (50.8%)

(.508) 71,051
n = 36,093

49.4%
n = 35,099
X2 = 61.3
df = 1
p < 0.001

-----------------------------------------------------------------------------------------------------------Race
White

N = 953,320 (50.1%)

(.501) 71,051
n = 35,597

40.8%
n = 28,989
X2 = 2458.3
df = 1
p < 0.001

Black

N = 201,700 (10.6%)

(.106) 71,051
n = 7,531

15.3%
n = 10,871
X2 = 2458.3
df = 1
p < 0.001

Hispanic N = 557,530 (29.3%)

(.293) 71,051
n = 20,818

41.4%
n = 29,415
X2 = 2458.3
df = 1
p < 0.001

-----------------------------------------------------------------------------------------------------------Age
18 - 64 years

N = 1,198,785 (63%)

(.63) 71,051
n = 44,762

70.5%
n = 60,598
X2 = 6671.1
df = 1
p < 0.001

65+

N = 190,283(10.7%)

(.107) 71,051
n = 7,602

12.2%
n = 10,453
X2 = 6671.1
df = 1
p < 0.001
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The remaining three research questions were answered in a publication in the
manuscript submitted to the journal BMC Oral Health, contained in Chapter 2.
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CHAPTER 2
HPV SCREENING & DETECTION
This chapter has been submitted (and accepted) for publication to the peerreviewed scientific journal BMC Oral Health and is presented in the style of that journal.
High-risk human papillomavirus (HPV) screening and detection in normal, healthy
patient saliva samples: a pilot cluster randomized study.
Deidre O Turner1, Shelley J Williams2, Ryan Bullen3, Jeremy Catmull3, Jesse Falk3,
Daniel Martin3, Jarom Mauer3, Annabel E Barber2, Shawn L Gerstenberger1, Karl
Kingsley3*.
1

University of Nevada, Las Vegas – School of Community Health Sciences, Department

of Environmental and Occupational Health, Las Vegas, Nevada, USA
2

University of Nevada, Reno – School of Medicine, Department of Surgery, Las Vegas,

Nevada, USA
3

University of Nevada, Las Vegas – School of Dental Medicine, Department of

Biomedical Sciences, Las Vegas, Nevada, USA
Abstract
Background: The human papillomaviruses (HPV) are a large family of nonenveloped DNA viruses, mainly associated with cervical cancers. Recent epidemiologic
evidence has suggested that HPV is an independent risk factor for oral cancers,
suggesting HPV may modulate the malignancy process in some tobacco- and alcoholinduced oral cancers, but may also be the primary oncogenic factor for inducing
carcinogenesis among non-smokers. Little evidence, however, is available regarding oral
HPV prevalence among healthy adults in the US. The goal of this study was to perform a
8

non-invasive, saliva-based HPV screening of normal healthy adults to assess oral HPV
prevalence.
Methods
Healthy, adult patients at a US dental school were randomly selected to
participate in a clustered pilot study. DNA was isolated from saliva samples and screened
for HPV16 using PCR. A small subset were subsequently screened using qPCR to
confirm analytical sensitivity and specificity.
Results: Chi-square analysis revealed the random patient sample was
representative of the general clinic population with respect to gender, race and age (p >
0.05). Four patient samples were found to harbor HPV16 DNA, representing 3.9% of the
total (n = 102). Three of the four HPV16-positive samples were from patients under 65
years of age and all four were female and Hispanic.
Conclusions: The successful recruitment and screening of healthy, adult patients
revealed HPV16 was present in a small subset of minority females. These results provide
new information about oral HPV status, which may help to contextualize results from
other studies that demonstrate oral cancer rates are increasing in the US among both
females and minorities and in some geographic areas – and may be associated with risk
factors other than tobacco and alcohol use. Although future studies may explore the role
of other factors that influence oral HPV exposure, as well as the short- and long-term
consequences of oral HPV infection, the results of this study may be of significant value
to further our understanding of oral health and disease risk.
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Background
The human papillomavirus (HPV) has been implicated as the cause of virtually all
cervical cancers worldwide [1-3]. These represent a large family of non-enveloped DNA
viruses that may be found integrated into the host genome, non-integrated or episomal, or
as a combination or mixture of these types in infected tissues [4-9]. HPV viruses infect
many types of epithelial cells, with intraepithelial neoplasias accounting for the
overwhelming majority of HPV-related cancers [10,11].
More than one hundred types of HPV have been identified and classified. These
HPV types may be the primary oncogenic or etiologic cause of cancer or are associated
with other dermatologic disorders, including the development of warts [12,13]. The HPV
strains determined to be oncogenic have been classified as high-risk, with HPV16 and
HPV18 the most prevalent - accounting for the overwhelming majority of all HPVassociated cancers [14]. Other HPV strains, more commonly associated with genital and
anal warts, or other skin and epithelial disorders, have been classified as low risk. These
include HPV types 6 and 11, among many others [15]. Although the majority of these
HPV strains were originally identified in cervical lesions, more recent evidence has
demonstrated their presence in other tissues including colorectal, penile, breast, lung, and
oral tissues [16-27].
Recent epidemiologic evidence has suggested that HPV is an independent risk
factor for oral cancer, revealing HPV in three times as many pre-cancerous oral lesions,
and almost five times as many oral cancers, compared with normal oral mucosa [28-30].
Although the traditional risk factors for developing oral cancer remain tobacco use and
heavy alcohol consumption, these data suggest other risk factors, such as HPV, may play
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significant roles in determining whether oral cancer develops and how quickly it may
progress [31-34]. Of all HPV types, the high-risk strains HPV16 and HPV18 are the
most commonly identified from biopsies of oral cancers [19-21], providing strong
evidence that HPV may be an independent risk factor for oral cancer.
The role of HPV in the oral cavity, however, may differ by anatomic site and also
by the particular strain of HPV infection [35]. For example, low-risk HPV strains 6 and
11 have been identified in benign laryngeal papillomas, common warts (verruca
vulgaris), and condyloma acuminatum [36-38]. These strains have also been found in
uncommon cancers, such as Ackerman’s (verrucous carcinomas) [39] and BuschkeLowenstein tumors [40]. Conversely, high-risk strains HPV-16, and to a lesser extent
HPV-18, are found in nearly half of all oral squamous cell carcinomas and epithelial
lesions [33,41,42].
The comparatively low presence of high-risk HPV in normal tissues and much
higher prevalence in oral cancers may suggest that HPV preferentially infects already
developing oral cancers [28-30]. HPV may then subsequently function to modulate the
malignancy process in developing or establish oral cancers, as has been observed in
studies of HPV infection in other developing cancers [23,43-45]. Recent epidemiologic
and case-control studies have demonstrated that patients with HPV-positive tumors had
significantly better response rates to chemotherapy and chemoradiation treatments when
compared with HPV-negative tumors [28,46-48].

Several in vitro studies have

investigated possible mechanisms that may account for these phenotypic changes in oral
cancers [49,50]. Evidence that HPV infection in oral cancers correlates with increased
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survival rates and better prognosis among some patients is now accumulating, possibly
due to changes in cellular responsiveness [45,51,52].
Despite these findings, rates of oral cancer in the United States (US) have been
rising among some subgroups within the population, and in specific geographic areas
[34,53-56]. The steady decrease in the number of current smokers in recent years,
combined with an ever-increasing percentage of never smokers in the US [33], suggests
that other risk factors are likely responsible, in part, for these observed increases. One
recent study found that although a majority of oral cancers in the US were linked with
tobacco and alcohol consumption, a significant minority were not [57].

More

importantly, this study found non-tobacco and non-alcohol related cases were six times
more likely to harbor HPV infections than controls. Based upon this information, it is
likely that HPV may modulate the malignancy process in some tobacco- and alcoholinduced oral cancers, thereby altering their phenotypes, but may also be the primary
oncogenic factor for inducing carcinogenesis among non-smokers.
To date, little evidence has been provided to estimate oral HPV prevalence among
healthy adults in the US.

A few select international studies have evaluated HPV

prevalence in healthy adults using biopsy samples, revealing prevalence rates that ranged
from 0 – 15% [41,58-62]. More recently, new international studies have begun to report
less invasive saliva-based testing methods to successfully screen for oral HPV infection
among healthy adults, revealing prevalence rates of approximately 20% [63-65]. To date,
there are few reports of saliva-based HPV screening studies of normal, healthy adults,
rather than oral cancer patients, to screen for oral prevalence in the US. Based upon this
information, the goal of this project was to perform a non-invasive, saliva-based HPV
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screening of normal healthy adults. This screening was performed in Nevada, a state
recently documented to have increasing rates of oral cancer – despite declining rates of
oral cancer nationally and declining rates of tobacco and alcohol use in the state [34,56].
Methods
Human Subjects
The protocol for this study titled “The Prevalence of Oral Human Papilloma Virus
(HPV) in the University of Nevada, Las Vegas - School of Dental Medicine (UNLVSDM) Clinic Population” was filed, amended, and approved by the UNLV Office of
Research Integrity – Human Subjects (OPRS#1002-3361) on April 9, 2010. In brief,
subjects were recruited by members of the UNLV-SDM Clinic during their dental visit
on one of fifteen (15) clinic dates. Informed Consent was required and was conducted
onsite. Inclusion criteria: subjects had to be eighteen (18) years old or older and must
agree to participate. Exclusion criteria: subjects younger than eighteen (18) years of age
and subjects with prior diagnosis of oral cancer were excluded from participation.
Saliva Collection Protocol
In brief, healthy adults who agreed to participate were given a small saliva
collection container, 50 mL sterile polypropylene tube, Fisher Scientific (Fair Lawn, NJ).
Participants were then asked to chew on a small piece of paraffin wax for one (1) minute
and then to expectorate. Each saliva sample was assigned a unique, randomly-generated
number to prevent research bias. Demographic information regarding the sample was
concurrently collected, which consisted of age, gender, and ethnicity only. Samples were
stored on ice until transport to a biomedical laboratory for analysis.
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DNA isolation and polymerase chain reaction (PCR)
To determine if any samples harbored the HPV virus, DNA was isolated from the
saliva

using

the

GenomicPrep

DNA

isolation

kit

(Amersham

Biosciences:

Buckinghamshire, UK), using the procedure recommended by the manufacturer. DNA
from each sample was then used to perform PCR with the Fisher exACTGene complete
PCR kit (Fisher Scientific: Fair Lawn, NJ) and a Mastercycler gradient thermocycler
(Eppendorf: Hamburg, Germany) using the following primers for HPV16 and
glyceraldehyde- 3- phosphate dehydrogenase (GAPDH), synthesized by SeqWright
(Houston, TX):
HPV16 forward primer, ATGTTTCAGGACCCACAGGA;
HPV16 reverse primer, CCTCACGTCGCAGTAACTGT.
GAPDH forward primer, ATCTTCCAGGAGCGAGATCC;
GAPDH reverse primer, ACCACTGACACGTTGGCAGT;
One μg of template DNA was used for each reaction. The initial denaturation
step ran for three minutes at 94°C. Thirty amplification cycles were run, consisting of 30
second denaturation at 94°C, 60 seconds of annealing at 58°C, and 30 seconds of
extension at 72°C. Final extension was run for five minutes at 72°C. The PCR reaction
products were separated by gel electrophoresis using Reliant 4% NuSieve® 3:1 Plus
Agarose gels (Lonza: Rockland, ME). Bands were visualized by UV illumination of
ethidium-bromide-stained gels and captured using a Kodak Gel Logic 100 Imaging
System and 1D Image Analysis Software (Eastman Kodak: Rochester, NY).
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Quantitative PCR assay
HPV16 primers were designed to amplify genomic DNA isolated from the saliva
samples. The first pair targeted HPV16 in the E6 region, with the second pair targeting
beta actin (β-actin). Real-time PCR conditions were conducted using the procedure
recommended by the manufacturer. The DNA quantity based on HPV16 gene data was
normalized using the DNA quantity of β-actin as a reference.
Statistical evaluation
Following the acquisition of saliva samples and HPV screening results,
demographic information from each sample was compared with the overall demographic
profile of the UNLV-SDM patient pool (N = 71, 051) using a chi-square (χ2) test, to
determine if any characteristic (gender, race, age) was different than expected among the
patients evaluated in this study (n = 102). A probability level of alpha (α) = 0.05 was
used to determine significance. Sensitivity and specificity were calculated as the
proportion of true positives and true negatives (cutoff value >0.1 copies/genome),
respectively.
Results
One hundred and fifty one (151) samples of saliva were collected from the
UNLV-SDM patient clinic between June 2 and October 1, 2010. The patients from
whom the randomly collected saliva samples were obtained were similar to the overall
UNLV-SDM clinic population with respect to gender (Table 1). More specifically, the
total number of females and males was roughly equal (52.3% and 47.7%, respectively)
and not significantly different (p > 0.05). However, there were slightly more White
patients in the study population (48.3%) than in the overall UNLV-SDM population
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(40.8%), which approached statistical significance (p < 0.1, p > 0.05). In addition, there
were also slightly fewer 18 – 64 year olds in the study population (80.8%) than in the
overall clinic (85.3%), which also approached statistical significance (p < 0.1, p > 0.05).
DNA was successfully isolated from one hundred and two (102) of the collected
saliva samples, which were subsequently screened for the presence of HPV-16 (Table 2).
Of the total number tested, only four (4) patient samples were determined to be HPV-16
positive, which represented 3.9% of the total screened. All four samples were taken from
females (p< 0.01) who were non-White (p<0.05), a result significantly different than
expected. Three of the four samples were from patients between 18 – 64 years of age,
and one sample came from a patient over 65 years of age.
Ten HPV-negative samples were selected at random to be screened in duplicate,
using quantitative PCR (qPCR) to provide quantitative assessment, as well as the four
HPV-positive samples (Table 3). These data confirm the four HPV-positive samples
were true positives, yielding normalized copy numbers significantly higher than
previously established cutoff values (>0.1 copies/genome). In addition, all ten HPVnegative samples were confirmed to have detectable levels below this cutoff value (range:
0.0003 – 0.0000016 copies/genome). Using more stringent (>0.001 copies/genome) and
less stringent (>0.1 copies/genome) cutoff values did not alter these results, providing
evidence that no false positives or false negatives were among the qPCR-screened
samples. The proportion of true positives (4/4 or 100%) and true negatives (10/10 or
100%) from this analysis suggested this analysis demonstrated sufficient sensitivity and
specificity, respectively.

16

Graphic analysis of qPCR results revealed striking differences in HPV-16 copy
numbers between HPV-negative and HPV-positive samples (Figure 1). Analysis of the
range of copy number/genome for the housekeeping gene (β-actin) within HPV16negative (range: 4 – 363 copies/genome) and HPV-positive samples (range: 75-1096)
were similar and well above the cutoff value (>0.1 copies/genome). However, analysis of
the range of copy number/genome for HPV-16 demonstrated clearly divergent values
among the HPV16-negative (range: 0.0003 – 0.0000016 copies/genome) and HPVpositive (range: 70 – 111 copies/genome) samples, which were easily distinguished using
the cutoff value (>0.1 copies/genome).
Discussion
The primary aim of this study was to perform a non-invasive, saliva-based HPV
screening of normal healthy adults within the patient population at UNLV-SDM. More
than one hundred samples were successfully collected and screened for HPV, revealing a
prevalence rate in this population of 3.9% (n = 102). Secondary analysis and screening
of these samples using qPCR demonstrated no false positives or false negatives,
providing further quantitative evidence of sufficient sensitivity and specificity within
these results.
These data suggest a prevalence rate that is slightly higher than the most recent
evidence, which demonstrated oral HPV prevalence in a multinational study of healthy,
cancer-free patients of approximately 1.3% (n = 1680) [66,67]. Over the past few
decades, a few select international studies have also evaluated HPV prevalence in healthy
adults using biopsy samples, which reported widely variable prevalence rates that ranged
from 0 – 15% [41,58-62].

The few published reports to screen for oral HPV infection
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among healthy adults using saliva-based testing methods, however, reported much higher
prevalence rates of approximately 20% [63-65]. The results of this current study provide
new data from a previously unscreened patient population (and geographic area) to
complement the growing corpus of information about oral HPV prevalence among
healthy adults.
This study also provides critically important information because it is among the
first to evaluate the prevalence of oral HPV infection among a patient population in
Nevada, one of the only US states to have increasing short-term oral cancer incidence and
mortality rates [56]. Although an analysis of the primary risk factors for oral cancer
revealed higher rates of tobacco use and smoking prevalence in Nevada than in
neighboring states, these rates were found to be steadily decreasing over time [34] –
suggesting other confounding variables or risk factors may also be important. Based
upon this evidence, evaluation of other independent risk factors for developing oral
cancer, including infection with high risk HPV, becomes crucial.
In addition, the results of this study found oral HPV infection only among patients
who were also minority and female. Although the vast majority of female and minority
patients in this study were found to have no evidence of oral HPV infection, recent
epidemiologic studies have shown that rates of oral cancer haven risen sharply among
females in the US despite declining rates among males [54]. Moreover, rates of oral
cancer have also been rising among minority populations in the US [53], despite an
overall decline among the general population, and the non-minority population, more
specifically [34,56]. Although the sample size in this study is limited, the results suggest
that further investigation may be warranted.
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This study had several limitations to be considered. Although the study was able
to recruit and screen a significant number of patients, due to the preliminary nature of this
pilot study, the overall sample size was somewhat limited. Future studies that are able to
allocate more significant time and resources, could significantly increase the overall
sample size evaluated. In addition, detailed demographic and behavioral data were not
designated as critical to the initial goals of this pilot study, however, the inclusion of
smoking and tobacco use, as well as more detailed information about other behaviors,
housing, education, income, and other socioeconomic indicators may provide additional
insights for future investigations. Finally, screening for other high-risk HPV strains,
including HPV18 or other oral infectious agents, may be possible in future studies with
more significant resources and personnel.
Conclusions
The goal of this study was to evaluate prevalence of HPV16 from a patient sample
in a pilot study at the UNLV-SDM.

This study successfully recruited patients and

screened samples that confirmed HPV16 was present in a small subset of the healthy,
adult patients. Moreover, the patients with oral HPV16 infection were both female and
minority. Although oral cancer has traditionally been associated with White males,
recent studies have found that rates of oral cancer are increasing in the US among both
females and minorities – and may be associated with risk factors other than tobacco and
alcohol use. Although future studies may explore the role of other factors that influence
oral HPV infections, as well as the short- and long-term consequences of oral HPV, the
results of this study may be of significant value as other dental, medical, health care, and
professional schools evaluate and integrate this evidence to further our understanding of
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oral health and disease risk.
Abbreviations
Human papillomavirus (HPV); Deoxyribonucleic acid (DNA); United States
(US); University of Nevada, Las Vegas - School of Dental Medicine (UNLV-SDM);
polymerase chain reaction (PCR); glyceraldehyde-3- phosphate dehydrogenase
(GAPDH); quantitative polymerase chain reaction (qPCR).
Competing interests
The authors declare they have no competing interests.
Author contributions
KK and SLG conceived, monitored, and coordinated the experimental design. RB,
JC, JF, DM, and JM were responsible for recruiting patients, informed consent, collecting
samples, and some biomedical analysis. DOT, KK, and SJW carried out the DNA
extractions, PCR, and qPCR analysis. KK, SJW and DOT were responsible for the data
analysis, as well as the writing and editing of this manuscript.
Acknowledgements
The authors would like to thank the University of Nevada, Reno (UNR) School of
Medicine, the UNLV School of Community Health Sciences and UNLV-SDM
Department of Biomedical Sciences and Office for Research for providing the supplies
and reagents for this initial pilot study.

20

References
1. Zhou W, Tyring SK, Brysk M, Chan T: Immortalization of differentiated human
keratinocytes by human papillomavirus (HPV) 16 DNA. Journal of Dermatological
Science 1996, 13:140-152.
2. Walboomers JMM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJF,
Peto J, Meijer CJLM, Munoz N: Human papillomavirus is a necessary cause of
invasive cervical cancer worldwide. J Pathol 1999, 189:12-19.
3. Clifford GM, Smith JS, Plummer M, Munoz N, Franceschi S: Human papillomavirus types
in invasive cervical cancer worldwide: a meta-analysis. Br J Cancer 2003, 88:63-73.
4. Das BC, Sharma JK, Gopalakrishna V, Luthra UK: Analysis by polymerase chain reaction
of the physical state of human papillomavirus type 16 DNA in cervical preneoplastic
and neoplastic lesions. J Gen Virol. 1992, 73( Pt 9):2327-36.
5. zur Hausen H: Papillomaviruses in human cancers. Proc Assoc Am Physicians. 1999,
111(6):581-7. Review
6. Kalantari M, Blennow E, Hagmar B, Johansson B: Physical state of HPV16 and
chromosomal mapping of the integrated form in cervical carcinomas. Diagn Mol
Pathol. 2001, 10(1):46-54.
7. zur Hausen H: Papillomaviruses and cancer: from basic studies to clinical application. Nat
Rev Cancer. 2002, 2(5):342-50.
8. de Villiers EM, Fauquet C, Broker TR, Bernard HU, zur Hausen H: Classification of
papillomaviruses. Virology 2004, 324(1):17-27. Review.
9. Ramanakumar AV, Goncalves O, Richardson H, Tellier P, Ferenczy A, Coutlee F, Franco EL:
Human papillomavirus (HPV) types 16, 18, 31, 45 DNA loads and HPV-16

21

integration in persistent and transient infections in young women. BMC Infect Dis.
2010, 10(1):326.
10. McCance DJ: Human papillomaviruses and cancer. Biochim Biophys Acta 1986, 823: 195205.
11. McCance DJ, Kopan R, Fuchs E, Laimins LA: Human papillomavirus type 16 alters
human epithelial cell differentiation in vitro. Proc Natl Acad Sci U S A 1988, 85:
7169-7173.
12. Sisk EA, Robertson ES: Clinical implications of human papillomavirus infection. Front
Biosci. 2002, 7:e77-84.
13. Satyaprakash AK, Tyring SK: Human papillomaviruses vaccine: a dermatologic
perspective. Indian J Dermatol Venereol Leprol. 2010, 76(1):14-9.
14. Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsaque X, Shah KV, Snijders PJ, Meijer
CJ: Epidemiologic classification of human papillomavirus types associated with
cervical cancer. N Engl J Med 2003, 348:518-527.
15. Dunne EF, Unger ER, Sternberg M, McQuillan G, Swan DC, Patel SS, Markowitz LE:
Prevalence of HPV infection among females in the United States. JAMA. 200,
297(8):813-9.
16. Williams GR, Talbot IC: Anal carcinoma--a histological review. Histopathology. 1994,
25(6):507-16.
17. Proby CM, Harwood CA: Role of human papillomaviruses in warts and cancer. Hosp
Med. 1998, 59(1):33-6.
18. Gillison ML, Shah KV: Chapter 9: Role of mucosal human papillomavirus in nongenital
cancers. J Natl Cancer Inst Monogr. 2003, 31:57-65.

22

19. Herrero R, Castellsague X, Pawlita M, Lissowska J, Kee F, Balaram P, Rajkumar T, Sridhar
H, Rose B, Pintos J, Fernandez L, Idris A, Jose Sanchez M, Nieto A, Talamini R, Tavani
A, Bosch FX, Reidel U, Snijders PJF, Meijer CJLM, Viscidi R, Munoz N, Franceschi S:
Human papillomavirus and oral cancer: The International Agency for Research on
Cancer multicenter study. J Natl Cancer I 2003, 95:1772-1783.
20. Kreimer AR, Clifford GM, Boyle P, Franceschi S: Human papillomavirus types in head
and neck squamous cell carcinomas worldwide: a systematic review. Cancer
Epidemiol Biomarkers Prev 2005, 14:467-475.
21. Syrjanen S: Human papillomavirus (HPV) in head and neck cancer. J Clin Virol 2005,
32:s59-66.
22. Amarante MK, Watanabe MA: The possible involvement of virus in breast cancer. J
Cancer Res Clin Oncol. 2009, 135(3):329-37. Epub 2008 Nov 14.
23. Kingsley K, Zuckerman J, Davis M, Matteucci M, Knavel A, Rinehart J, Tran V,
Woyciehowsky D, Jenkins P, Yu Rui, Nguyen DH, O’Malley S: Induction of
Differential Growth in vitro by High-risk Human Papillomavirus in Human Breast
Cancer Cell Lines is Associated with Caspase Dysregulation. Journal of Cancer
Science and Therapy 2009 1(2): 62-71.
24. Miralles-Guri C, Bruni L, Cubilla AL, Castellsagué X, Bosch FX, de Sanjosé S: Human
papillomavirus prevalence and type distribution in penile carcinoma. J Clin Pathol.
2009, 62(10):870-8. Epub 2009 Aug 25.
25. Rezazadeh A, Laber DA, Ghim SJ, Jenson AB, Kloecker G: The role of human papilloma
virus in lung cancer: a review of the evidence. Am J Med Sci. 2009, 338(1):64-7.

23

26. Shukla S, Bharti AC, Mahata S, Hussain S, Kumar R, Hedau S, Das BC: Infection of
human papillomaviruses in cancers of different human organ sites. Indian J Med
Res. 2009, 130(3):222-33.

27. Pow-Sang MR, Ferreira U, Pow-Sang JM, Nardi AC, Destefano V: Epidemiology and
natural history of penile cancer. Urology. 2010, 76(2 Suppl 1):S2-6.
28. Gillison ML, Koch WM, Capone RB, Spafford M, Westra WH, Wu L, Zahurak ML, Daniel
RW, Viglione M, Symer DE, Shah KV, Sidransky D: Evidence for a causal association
between human papillomavirus and a subset of head and neck cancers. J Natl
Cancer Inst 2000, 92:675-677.
29. Miller CS, Johnstone BM: Human papillomavirus as a risk factor for oral squamous cell
carcinoma: a meta-analysis, 1982-1997. Oral Surg Oral Med Oral Pathol 2001,
91:622-635.
30. van Houten VM, Snijders PJ, van den Brekel MW, Kummer JA, Meijer CJ, van Leeuwen B,
Denkers F, Smeele LE, Snow GB, Brakenhoff RH: Biological evidence that human
papillomaviruses are etiologically involved in a subgroup of head and neck
squamous cell carcinomas. Int J Cancer 2001, 93:232-235.
31. Frisch M, Hjalgrim H, Jaeger AB, Biggar RJ: Changing patterns of tonsillar squamous
cell carcinoma in the United States. Cancer Causes Control. 2000, 11(6):489-95.
32. Shiboski CH, Schmidt BL, Jordan RC: Tongue and tonsil carcinoma: increasing trends in
the U.S. population ages 20-44 years. Cancer. 2005, 103(9):1843-9.
33. Goon PK, Stanley MA, Ebmeyer J, Steinsträsser L, Upile T, Jerjes W, Bernal-Sprekelsen M,
Görner M, Sudhoff HH: HPV & head and neck cancer: a descriptive update. Head
Neck Oncol. 2009, 1:36.
24

34. Bunnell A , Pettit N, Reddout N, Sharma K, O’Malley S, Chino M, Kingsley K: Analysis of
primary risk factors for oral cancer from select US states with increasing rates.
Tobacco Induced Diseases 2010, 8:5.
35. Termine N, Panzarella V, Falaschini S, Russo A, Matranga D, Lo Muzio L, Campisi G: HPV
in oral squamous cell carcinoma vs head and neck squamous cell carcinoma
biopsies: a meta-analysis (1988-2007). Ann Oncol. 2008, 19(10):1681-90. Epub 2008
Jun 16.
36. Monk BJ, Tewari KS: The spectrum and clinical sequelae of human papillomavirus
infection. Gynecol Oncol. 2007, 107(2 Suppl 1):S6-13.
37. Goon P, Sonnex C, Jani P, Stanley M, Sudhoff H: Recurrent respiratory papillomatosis:
an overview of current thinking and treatment. Eur Arch Otorhinolaryngol. 2008,
265(2):147-51. Epub 2007 Nov 29.
38. Feller L, Khammissa RA, Wood NH, Lemmer J: Epithelial maturation and molecular
biology of oral HPV. Infect Agent Cancer. 2009, 4:16.
39. Akyol A, Anadolu R, Anadolu Y, Ekmekci P, Gürgey E, Akay N: Multifocal
papillomavirus epithelial hyperplasia: successful treatment with CO2 laser therapy
combined with interferon alpha-2b. Int J Dermatol. 2003, 42(9):733-5.
40. Erkek E, Basar H, Bozdogan O, Emeksiz MC: Giant condyloma acuminata of BuschkeLöwenstein: successful treatment with a combination of surgical excision, oral
acitretin and topical imiquimod. Clin Exp Dermatol. 2009, 34(3):366-8. Epub 2008
Oct 30.

25

41. Ostwald C, Müller P, Barten M, Rutsatz K, Sonnenburg M, Milde-Langosch K, Löning T:
Human papillomavirus DNA in oral squamous cell carcinomas and normal mucosa.
J Oral Pathol Med. 1994, 23(5):220-5.
42. Ostwald C, Rutsatz K, Schweder J, Schmidt W, Gundlach K, Barten M: Human
papillomavirus 6/11, 16 and 18 in oral carcinomas and benign oral lesions. Med
Microbiol Immunol. 2003, 192(3):145-8. Epub 2002 Nov 1.
43. Kan C-Y, Iacopetta BJ, Lawson JS, Whitaker NF: Identification of human papillomavirus
DNA sequences in human breast cancer. British Journal of Cancer. 2005, 93:946-948.
44. Khan NA, Castillo A, Koriyama C, Kijima Y, Umekita Y, Ohi Y, Higashi M, Sagara Y,
Yoshinaka H, Tsuji T, Natsugoe S, Douchi T, Eizuru Y, Akiba S: Human
papillomavirus detected in female breast carcinomas in Japan. Br J Cancer 2008,
99(3): 408-414.
45. Jung AC, Briolat J, Millon R, de Reynies A, Rickman D, Thomas E, Abecassis J, Clavel C,
Wasylyk B: Biological and clinical relevance of transcriptionnally active human
papillomavirus (HPV) infection in oropharynx squamous cell carcinoma. Int J
Cancer. 2009 [Epub ahead of print].
46. Schwartz SR, Yueh B, McDougall JK, Daling JR, Schwartz SM: Human papillomavirus
infection and survival in oral squamous cell cancer: a population-based study.
Otolaryngol Head Neck Surg. 2001, 125(1):1-9.
47. Badaracco G, Rizzo C, Mafera B, Pichi B, Giannarelli D, Rahimi SS, Vigili MG, Venuti A:
Molecular analyses and prognostic relevance of HPV in head and neck tumours.
Oncol Rep. 2007, 17(4):931-9.

26

48. Fakhry C, Westra WH, Li S, Cmelak A, Ridge JA, Pinto H, Forastiere A, Gillison ML:
Improved survival of patients with human papillomavirus-positive head and neck
squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst. 2008,
100(4):261-9. Epub 2008 Feb 12.
49. Kingsley K, Johnson D, O’Malley S: Transfection of oral squamous cell carcinoma with
human papillomavirus-16 induces proliferative and morphological changes
independent of cellular adhesion in vitro. Cancer Cell International, 2006, 6:14.
50. Reddout N, Christensen T, Bunnell A, Jensen D, Johnson D, O’Malley S, Kingsley K: High
risk HPV types 18 and 16 are potent modulators of oral squamous cell carcinoma
phenotypes in vitro. Infectious Agents and Cancer 2007, 2 (1): 21.
51. Zhao D, Xu QG, Chen XM, Fan MW: Human papillomavirus as an independent
predictor in oral squamous cell cancer. Int J Oral Sci. 2009, 1(3):119-25.
52. Mehta V, Yu GP, Schantz SP: Population-based analysis of oral and oropharyngeal
carcinoma: Changing trends of histopathologic differentiation, survival and patient
demographics. Laryngoscope. 2010, 120(11):2203-12.
53. Swango PA: Cancers of the oral cavity and pharynx in the United States: an
epidemiologic overview. J Public Health Dent. 1996, 56:309-318.
54. Shiboski CH, Shiboski SC, Silverman S Jr.: Trends in oral cancer rates in the United
States, 1973-1996. Community Dent Oral Epidemiol. 2000, 28:249-256.
55. Edwards BK, Howe HL, Ries LA, Thun MJ, Rosenberg HM, Yanick R, Wingo PA, Jemal A,
Feigal EG: Annual report to the nation on the status of cancer, 1973-1999, featuring
implications of age and aging on U.S. cancer burden. Cancer. 2002, 94:2766-2792.

27

56. Kingsley K, O’Malley S, Chino M: Analysis of oral cancer epidemiology in the US
reveals state-specific trends: implications for oral cancer prevention. BMC Public
Health 2008, 8(1): 87.
57. Andrews E, Seaman WT, Webster-Cyriaque J: Oropharyngeal carcinoma in non-smokers
and non-drinkers: a role for HPV. Oral Oncol. 2009, 45(6):486-91. Epub 2008 Nov
21.
58. Mao EJ: Prevalence of human papillomavirus 16 and nucleolar organizer region counts
in oral exfoliated cells from normal and malignant epithelia. Oral Surg Oral Med
Oral Pathol Oral Radiol Endod. 1995, 80(3):320-9.
59. Cruz IB, Snijders PJ, Steenbergen RD, Meijer CJ, Snow GB, Walboomers JM, van der Waal
I: Age-dependence of human papillomavirus DNA presence in oral squamous cell
carcinomas. Eur J Cancer B Oral Oncol. 1996, 32B(1):55-62.
60. Bouda M, Gorgoulis VG, Kastrinakis NG, Giannoudis A, Tsoli E, Danassi-Afentaki D,
Foukas P, Kyroudi A, Laskaris G, Herrington CS, Kittas C: "High risk" HPV types are
frequently detected in potentially malignant and malignant oral lesions, but not in
normal oral mucosa. Mod Pathol. 2000, 13(6):644-53.
61. do Sacramento PR, Babeto E, Colombo J, Cabral Ruback MJ, Bonilha JL, Fernandes AM,
Pereira Sobrinho JS, de Souza FP, Villa LL, Rahal P: The prevalence of human
papillomavirus in the oropharynx in healthy individuals in a Brazilian population. J
Med Virol. 2006, 78(5):614-8.
62. González JV, Gutiérrez RA, Keszler A, Colacino Mdel C, Alonio LV, Teyssie AR, Picconi
MA: Human papillomavirus in oral lesions. Medicina (B Aires). 2007, 67(4):363-8.

28

63. Gonçalves AK, Giraldo P, Barros-Mazon S, Gondo ML, Amaral RL, Jacyntho C: Secretory
immunoglobulin A in saliva of women with oral and genital HPV infection. Eur J
Obstet Gynecol Reprod Biol. 2006, 124(2):227-31. Epub 2005 Sep 6.
64. SahebJamee M, Boorghani M, Ghaffari SR, AtarbashiMoghadam F, Keyhani A: Human
papillomavirus in saliva of patients with oral squamous cell carcinoma. Med Oral
Patol Oral Cir Bucal. 2009, 14(10):e525-8.
65. Seaman WT, Andrews E, Couch M, Kojic EM, Cu-Uvin S, Palefsky J, Deal AM, WebsterCyriaque J: Detection and quantitation of HPV in genital and oral tissues and fluids
by real time PCR. Virol J. 2010, 7:194.
66. Kreimer AR, Villa A, Nyitray A, Abrahamsen ME, Papenfuss MR, Smith D, Hildesheim A,
Villa LL, Lazcano-Ponce E, Giuliano AR: The epidemiology of oral HPV infection
among a multinational sample of healthy men. Cancer Epidemiol Biomarkers Prev.
2010 [Epub ahead of print].
67. Kreimer AR, Bhatia RK, Messeguer AL, González P, Herrero R, Giuliano AR: Oral human
papillomavirus in healthy individuals: a systematic review of the literature. Sex
Transm Dis. 2010, 37(6):386-91.

29

Figures and Figure legends

10000

β‐actin HPV16

β‐actin HPV16

Copy number / genome

1000
100
10
1
0.1
0.01
0.001
0.0001
0.00001
0.000001

HPV16-positive
samples

HPV16-negative
samples

Figure 1. Graphic analysis of qPCR HPV screening results.

Plotting of copy

number/genome for housekeeping gene (β-actin) was similar from samples of HPVpositive (range: 75-1096) and HPV-negative samples (range: 4 – 363 copies/genome).
Copy number/genome using qPCR was significantly above the cutoff value (>0.1
copies/genome), confirming the HPV-positive samples did harbor HPV DNA (range: 70
– 111 copies/genome). Values for HPV-negative samples were well beneath the cutoff
value (range: 0.0003 – 0.0000016 copies/genome).
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Tables
Table 1. Demographic analysis of study participants
________________________________________________________________________
Variables

UNLV-SDM

Study sample

p-value

________________________________________________________________________
Gender
Female

n = 35,952 (50.6%)

n = 79 (52.3%)

Male

n = 35,099 (49.4%)

n = 72 (47.7%)

White

n = 28,989 (40.8%)

n = 73 (48.3%)

Non-White

n = 42,062 (59.2%)

n = 78 (51.7%)

18 - 64 years

n = 60,598 (85.3%)

n = 122 (80.8%)

65 +

n = 10,453 (14.7%)

n = 29 (19.2%)

p > 0.5

Race
p > 0.10

Age
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p > 0.10

Table 2. Analysis of HPV-16 DNA PCR screening
________________________________________________________________________
Variables

HPV-16 negative

HPV-16 positive

n = 98

n=4

________________________________________________________________________
Gender
Female

n = 58 (56.9%)

n = 4 (3.9%)

Male

n = 40 (39.2%)

n = 0 (0.0%)

White

n = 44 (43.1%)

n = 0 (0.0%)

Non-White

n = 54 (52.9%)

n = 4 (3.9%)

18 - 64 years

n = 81 (79.4%)

n = 3 (2.9%)

65 +

n = 17 (16.7%)

n = 1 (0.1%)

Race

Age
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Table 3. Comparison of HPV screening methods
________________________________________________________________________
Sample ID
PCR screening
qPCR screening
True positive False positive
________________________________________________________________________
2527
Positive (+)
70 copies/genome
+
2430
Positive (+)
111 copies/genome +
2819
Positive (+)
87 copies/genome
+
2718
Positive (+)
96 copies/genome
+
________________________________________________________________________
Sample
PCR screening
qPCR screening
True negative False negative
> 0.001 copies/genome
________________________________________________________________________
2858
Negative (-)
0.0000148
+
2108
Negative (-)
0.0005
+
2424
Negative (-)
0.0003
+
2003
Negative (-)
0.0000016
+
2208
Negative (-)
0.0003
+
2739
Negative (-)
0.0007
+
2051
Negative (-)
0.00001
+
2809
Negative (-)
0.00004
+
2782
Negative (-)
0.00008
+
2821
Negative (-)
0.000036
+
________________________________________________________________________
Change in threshold value
True negatives
True positives
________________________________________________________________________
Cutoff copies/genome > 0.1
10/10 (100%)
4/4
(100%)
Cutoff copies/genome > 0.01
10/10 (100%)
4/4
(100%)
Cutoff copies/genome > 0.001
10/10 (100%)
4/4
(100%)
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CHAPTER 3

DISCUSSION & CONCLUSION
General Discussion
Socioeconomic status (SES) is a predictor of health which reflects social
influence and individual factors, environmental exposures, stressors, and health behaviors
in populations (Benard et al., 2008). SES includes income, education, occupation,
location of residence, poverty level, and race. Disparities of race and gender are
differences in patterns and exposure to risk factors. Many types of barriers to screening
and education exist when health disparities are present.
The health belief model fits the realm of this study because it can help explain
why one would or would not use available preventive services. In this case, the reasoning
of why women and minorities infrequently receive pap smears, breast exams, or oral
cancer screening is measurable. Perceived susceptibility, perceived severity, perceived
benefits, and perceived barriers are the four constructs that outline the health belief
model. Self-efficacy evaluates the individual’s confidence in their ability to perform the
action. The health belief model can assist in answering why a particular behavior occurs
and identify ways to change the behavior. Perceived susceptibility asks the question
whether women and minorities believe that they are at risk for developing HPV, cervical
cancer, breast cancer, and even oral cancer. Perceived severity is whether at risk
individuals are aware that HPV is the primary cause of cervical cancer, seen in 50% of
breast cancer biopsies, and now seen in oral cancer patients. The perceived benefit of
screening is potential early detection for cervical, breast, and oral cancers, thus
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preventing cancer. Perceived barriers are what prevent at-risk individuals from getting
screened.
Barriers include access to health care, refusal to access care, perceived risks,
follow up diagnosis of cancer, cultural beliefs, and most importantly lack of
communication and education regarding preventive care options. Down’s et al., (2010)
identified five barriers to health. These five include availability (volume and type of
service); accessibility (location of service vs location of clientele); accommodation (ease
of obtaining it); affordability (cost and perceived ability to pay); and acceptability
(perceptions about practice characteristics). Minorities may be less likely to have health
insurance, are likely to face screening barriers, and are less likely to receive treatment.
Low income, low education, and being a minority woman are risk factors for developing
HPV. Although access to health care may exist, it may be refused. Women in poverty
tend to only access health care in urgent or emergency situations. In addition, minorities
with a native language other than English may have difficulties communicating due to
language barriers.
Healthy People 2020 identified disparity as a particular type of health difference
that is closely linked with social, economic, and/or environmental disadvantage (Healthy
People 2020). The CDC (2009) referred to health disparities as differences in health
outcomes and their determinants between segments of the population, as defined by
social, demographic, environmental, and geographic attributes. Health disparities are
important indicators of community health and provide information for decision making
and potential intervention strategies used to reduce preventable morbidity and mortality
(CDC, 2009).
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Health disparities need to be addressed in order to increase knowledge among
women and minorities about risks, screening, treatment, and diagnosis. These
communities needs to be educated about HPV and its links to cervical, breast, and oral
cancers and may be unaware of its association with different types of cancers. According
to the CDC (2009), the Department of Health and Human Services has recognized cancer
screening and management as one of six focus areas in which minorities face racial
disparities in access to health and outcomes. “African American (Black) women are more
than twice as likely to die of cervical cancer than white women and are more likely to die
of breast cancer than are women of any other racial or ethnic group” (CDC, 2009).
Media, including television, radio, periodicals, and the internet, are potential
sources of information, but more specific information and awareness projects could be
conducted to improve health literacy and health education for women and minorities.
Media and public health campaigns, for example, might consider inclusion of several
types of information, including some background information about HPV, modes and
methods of transmission, prevention strategies, treatment, as well as the risk of
developing cancer. In addition, individuals also need to be informed that HPV can be
asymptomatic. Anhang et al., (2004) suggested that six points be emphasized when
providing pertinent information about HPV to individuals. The six points included: (1)
HPV is transmitted sexually; (2) HPV is very common; (3) most women with HPV will
not develop cervical cancer; (4) HPV’s most common prognosis is infection clearing
itself prior to treatment; (5) purpose of a Pap smear is to detect HPV-related lesions in the
cervix suggestive of precancerous or cancerous conditions; and (6) most women who test
positive for high risk HPV will not be diagnosed with cervical cancer or a precursor on
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further evaluation (Anhang et al., 2004). In Healthy People 2020 (2010), the goal for
health disparities is to achieve health equity, eliminate disparities, and improve health of
all groups (Healthy People 2020, 2010).
As the principal investigator of this project, HPV became an interesting and
important topic following the presentation of Dr. Karl Kingsley’s group (class project) on
immunizations. Although some prior knowledge and background has been circulated
through commercial advertisement for the new HPV vaccine, Gardasil, little information
regarding any other aspects of HPV has been available from the popular media and press.
The presentation advised us of the links that HPV had to cervical, breast, and oral cancers
and how minorities and women were most affected. As a woman and a minority, these
issues represent distinct priorities. Based upon a first-hand experience, it may be a strong
possibility that these at-risk communities have similar barriers to information. As a public
health graduate student, an addition goal for this paper may be to serve as an educational
resource for women and minorities with respect to HPV, its risks, and prevention.
Although there are many issues regarding HPV and women/minority health
(cervical, breast, oral health), as the principal investigator, there was a major opportunity
to take part in one specific project that targeted oral HPV. This allowed the chance to
explore a population that is representative of minorities and females while discovering
something new that nobody else has done in the US, an oral HPV screening of healthy
adults in the US.
Minorities tend to be underrepresented in research studies, possibly due to barriers
such as fear, lack of trust, and lack of education. Overcoming these barriers could allow
minorities to participate in more research studies allowing researchers to establish
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community specific education and awareness. Eliminating barriers could improve
screening and lower morbidity and mortality rates in minorities and women. Screening is
a preventive measure that can lower incidence rates in minorities and women and extend
their duration of life. Screening, education, and eliminating barriers are essential for
lowering risks in women and minority patients.
Future studies
Future studies conducted between the School of Community Health Sciences and
Dental Medicine should continue the oral HPV screening while testing for HPV 18,
another high risk strain, in addition to HPV 16. Also, a learning module should be created
for females and minorities to educate about HPV and its relation to cervical, breast, and
oral health. In addition, future students should see how many UNLV-SDM patients
(female) have pap smears and dental screenings (male/female) regularly.
Conclusions and Significance
Analysis of the UNLV-SDM patient population revealed a higher percentage of
females and minorities than in the local community, Clark County. Analysis of the
demographic information from the saliva samples revealed that these samples were
representative of the UNLV-SDM patient pool. Four (4) samples tested positive for
HPV16 (all from women and minority participants) from more than one hundred samples
screened (n=102). This study is significant because it is the first saliva-based oral HPV
screening on healthy adults to be completed in the U.S. and only the third study of its
kind overall.
In conclusion, although this study provides valuable information, it also had
several limitations. These include the limited screening for only one HPV type, HPV16.
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HPV16 is the most common HPV strain found in the oral cavity and was therefore
selected for this pilot study, although future studies could evaluate other high-risk HPV
strains, such as HPV18. In addition, detailed demographic information were not obtained
in this study, although future studies could evaluate other demographic variables,
including tobacco and alcohol use, education, income, and even knowledge of HPV.
Even though the prevalence of HPV16 in this study was relatively low (3.9%), it is
comparable to other studies of oral HPV (range 0 -21%).

Future studies might

incorporate larger sample sizes and provide alternative sites for screening other at-risk
populations.
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